Stock MDNA MEDICENNA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.41 CAD +1.69% Intraday chart for Medicenna Therapeutics Corp. +6.17% +473.81%
Jun. 03 Medicenna Reports "Significant" Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp MT
Jun. 03 Medicenna Brief: Reporting "Significant" Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a "Matched External Control Arm" MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024
Medicenna Therapeutics Up 13% After Flagging Presentations
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024
Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting
Medicenna Reports Q3 Net Loss $5.0 Million
Medicenna Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors
Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck?s Pembrolizumab
Medicenna Therapeutics Extends Period to Exercise Certain Warrants; Down 1.2%
Medicenna Announces "Compelling" Survival Benefit From Phase 2b Study in Recurrent Glioblastoma at NeuroOncology Meeting
Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp
Medicenna Reports Q2 Net Loss of $0.05 Per Share; Cash Runway Extended Into Q1 of Calendar 2025
Medicenna Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma
Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting
Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Medicenna Presents Preclinical Data on MDNA113 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
Medicenna Slumps 24% As Reports Nasdaq Delisting, Downsizes Management Team
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDNA Stock
  4. News Medicenna Therapeutics Corp.
  5. Other languages